Danish Pharmacovigilance Update, 20 October 2011

In this issue of Danish Pharmacovigilance Update:

• Use of medicines involving a risk of serious and life-threatening skin reactions
• European Medicines Agency (EMA) to investigate the possible connection between orlistat and rare cases of severe liver toxicity
• EMA completes review of peritoneal dialysis solutions from Baxter A/S
• Product information for Revlimid® to be updated
• The Danish Medicines Agency has received a report of a death in connection with use of the smoking cessation product Champix®
• List of medicines most frequently involved in serious adverse drug events to help minimise risks in the medication process
• New restrictions in use, further contraindications and warnings for Multaq® (dronedarone)
• Adverse reactions in connection with the childhood immunisation programme in the first half of 2011

Download the newsletter in the box to the right.